Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2019 | PROMISE-meso: pembrolizumab vs. standard chemotherapy for mesothelioma

Sanjay Popat • 29 Sep 2019
ESMO 2019
Lung Cancer Mesothelioma Pembrolizumab
PROMISE-meso

Sanjay Popat, PhD, MBBS, FRCP, Royal Marsden NHS Foundation Trust, London, UK, provides and update on the (ETOP 9-15) PROMISE-meso trial (NCT02991482 ), a multicentre randomized phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Sanjay Popat

Comparing selpercatinib and pralsetinib in RET-positive NSCLC
1:19
Comparing selpercatinib and pralsetinib in RET-positive NSCLC
Sanjay Popat • 29 May 2026
AcceleRET-Lung: pralsetinib vs SOC in first-line RET fusion-positive NSCLC
6:11
AcceleRET-Lung: pralsetinib vs SOC in first-line RET fusion-positive NSCLC
Sanjay Popat • 29 May 2026
Enhancing survivorship and long-term management of ALK+ NSCLC
2:42
Enhancing survivorship and long-term management of ALK+ NSCLC
Sanjay Popat • 20 Oct 2025
Elucidating the novel standard of care for EGFR-positive lung cancer
1:52
Elucidating the novel standard of care for EGFR-positive lung cancer
Sanjay Popat • 20 Oct 2025

Related Videos

Zidesamtinib in TKI-naïve patients with ROS1+ NSCLC: insights from the ARROS-1 trial
4:59
Zidesamtinib in TKI-naïve patients with ROS1+ NSCLC: insights from the ARROS-1 trial
Alexander Drilon • 7 Oct 2026
WCLC 2026 highlights: T-DXd in HER2-mutant NSCLC and advances in targeted therapies
0:59
WCLC 2026 highlights: T-DXd in HER2-mutant NSCLC and advances in targeted therapies
Alexander Drilon • 7 Oct 2026
Activity of zidesamtinib for ROS1+ NSCLC in TKI-naïve and pre-treated patients
0:52
Activity of zidesamtinib for ROS1+ NSCLC in TKI-naïve and pre-treated patients
Alexander Drilon • 7 Oct 2026
The role of AI in surgery for patients with lung cancer
1:04
The role of AI in surgery for patients with lung cancer
Kelvin Lau • 14 Sep 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals